Mepolizumab for Eosinophilic Fasciitis

• Status: Not yet recruiting
• Trial end date: 2023-12-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a proof of concept pilot study to investigate the efficacy of mepolizumab in the treatment of eosinophilic fasciitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Male and female patients 18 years or older.

• History and physical examination consistent with EF

• Full thickness skin biopsy characteristic of eosinophilic fascitis and/or MRI radiographic findings characteristic of EF

• Documented peripheral eosinophilia (≥500 microliter)

• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and

• Patients who read and sign an approved informed consent for this study

Exclusion Criteria:

• Eosinophilic fascitis disease duration > 5 years

• Known history of adverse reaction to mepolizumab (Nucala)

• Pregnant females

• Females actively trying to conceive

• Vulnerable study population

• Asthma requiring inhaled cortiosteroids